Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
featured
Have been diagnosed with moderate to severe Ulcerative Colitis?

Have been diagnosed with moderate to severe Ulcerative Colitis?

  • 72 views
  • 08 Nov, 2020
  • 1 location
featured
PSA-006

PSA-006

  • 192 views
  • 23 Nov, 2020
  • 1 location
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G 3, moderate or severe). Approximately 332 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 …

topical agents
apremilast
plaque psoriasis
cc-10004
  • 210 views
  • 23 Dec, 2020
  • 120 locations
A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

option 2
cc-10004
steroidal anti-inflammatory drugs
tubal ligation
hysterectomy
  • 190 views
  • 12 Dec, 2020
  • 99 locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque

topical agents
cc-10004
systemic therapy
plaque psoriasis
apremilast
  • 98 views
  • 16 Dec, 2020
  • 192 locations
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy

option 2
cervical cap
cc-10004
hormonal contraception
apremilast
  • 0 views
  • 23 Nov, 2020
  • 6 locations